Verastem Inc. (VSTM) Fundamentals

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.
SHARE INFORMATION
Market Cap$ 173,214,920
Shares Outstanding187,807,568
Float164,764,851
Percent Float87.73%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 2,053,000
Latest Fiscal EPS$ -0.42
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions318
Institutional Holdings Date2022-08-31
Institutional Bought Previous 3 Months11,273,550
Institutional Holdings Percent79.4%
Institutional Sold Previous 3 Months36,518,195
Insider Holdings Date2022-08-31
Insider Bought Previous 3 Months375,000
Insider Holdings Percent2.1
Insider Sold Previous 3 Months13,272
Insider Shares Owned4,018,219
TRADING INFO
52 Week High$ 3.30
52 Week Low$ 0.90
52 Week High Change$ -71.27
21 Day Moving Average$ 1.1422
21 Day Extended Moving Average$ 1.1116
50 Day Moving Average$ 1.1819
50 Day Extended Moving Average$ 1.1664
200 Day Moving Average$ 1.3828
200 Day Extended Moving Average$ 1.4829
10 Day Average Volume974,514
20 Day Average Volume747,902
30 Day Average Volume1,318,409
50 Day Average Volume1,253,778
Alpha-0.004379
Beta0.7350
Standard Deviation0.217996
R20.028945
7 Day Price Change$ -0.1977
7 Day Percent Change-17.65%
21 Day Price Change$ -0.2277
21 Day Percent Change-19.8%
30 Day Price Change$ -0.3477
30 Day Percent Change-27.38%
Month to Date Price Change$ -0.2377
Month to Date Percent Change-20.49%
Quarter to Date Price Change$ -0.2377
Quarter to Date Percent Change-20.49%
180 Day Price Change$ -0.2677
180 Day Percent Change-22.5%
200 Day Price Change$ -0.4877
200 Day Percent Change-34.59%
Year to Date Price Change$ -1.13
Year to Date Percent Change-55.01%

Verastem Inc. (VSTM) Key Ratios

PROFITABILITY
EBIT Margin-2,211.1%
EBITDA Margin-2,211.1%
Pre-Tax Profit Margin0.0%
Profit Margin Count-47.93%
Gross Margin100.0%
Profit Margin TOT-47.93%
INCOME STATEMENTS
Revenue$ 3,143,000
Revenue Per Share$ 0.0167
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book3.20
Total Debt To Equity0.50
Int Coverage-8.00
Current Ratio4.90
Leverage Ratio1.40
Quick Ratio4.70
Long Term Debt To Capital0.33
VALUATION MEASURES
PE Ratio-2.10
Enterprise Value$ 106,060,919
Price to Sales55.1113
Price to Free Cash-3.30
PE High Last 5 Years-2.30
Price To Book3.20
Price To Cash Flow0.00
PE Low Last 5 Years-3.50
Price to Tangible Book3.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover17.80
Invoice Turnover10.20
Assets Turnover0.00
Return Assets-74.50
Return on Equity-118.60
Return on Capital-72.31

Verastem Inc. (VSTM) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOBrian M. Stuglik
Emplyoees48
Last AuditUQ
CIK0001526119
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address117 Kendrick Street
Suite 500
Needham, MA 2494
Websitehttps://www.verastem.com
Facsimile-
Telephone+1 781 292-4200
Emailinfo@verastem.com


Your Recent History
NASDAQ
VSTM
Verastem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.